Amaia Zabala-Letona

Amaia Zabala-Letona

Auto-generated profile, based on publicly available information

Amaia Zabala-Letona

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
VTVeronica Torrano
Veronica Torrano
LVLorea Valcarcel-Jimenez
Lorea Valcarcel-Jimenez
ACAna Rosa Cortazar
Ana Rosa Cortazar
XLXiaojing Liu
Xiaojing Liu
JUJelena Urosevic
Jelena Urosevic
ACArkaitz Carracedo
Arkaitz Carracedo
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.

28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
AZAmaia Zabala-Letona
Amaia Zabala-Letona
AAAmaia Arruabarrena-Aristorena
Amaia Arruabarrena-Aristorena
NMNatalia Martín-Martín
Natalia Martín-Martín
SFSonia Fernandez-Ruiz
Sonia Fernandez-Ruiz
JSJames D. Sutherland
James D. Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
MTOR complex 1 signalling regulates polyamine metabolism and thereby promotes tumorigenesis, through regulation of the stability of a key enzyme, AMD1. The mTOR pathway regulates multiple metabolic pathways in cancers but knowledge of how oncogenic signals regulate polyamine production, which is important in spreading cancer cells, is limited. Arkaitz Carracedo and colleagues add to the existing knowledge. Using a mixture of metabolic analysis techniques, they show that mTOR signalling regulates polyamine metabolism and thereby promotes tumorigenesis through regulation of the stability of a key enzyme, AMD1. They validated this pathway in mouse and human cancer specimens and found that ADM1 is upregulated in prostate cancer specimens with activated mTORC1. This adds to the complexity of cancer cell metabolism and offers new therapeutic avenues. Activation of the PTEN–PI3K–mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.

5 January 2018 in Science Advances
Verified
Journal Article
Open access
AAAmaia Arruabarrena-Aristorena
Amaia Arruabarrena-Aristorena
AZAmaia Zabala-Letona
Amaia Zabala-Letona
ACArkaitz Carracedo
Arkaitz Carracedo
Polyamine metabolism exhibits tight cross-talk with oncogenic signaling, thus playing a central role in cancer dynamics.

12 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FRFelix Royo
Felix Royo
PZPatricia Zuñiga-Garcia
Patricia Zuñiga-Garcia
VTVerónica Torrano
Verónica Torrano
ALAna Loizaga
Ana Loizaga
PSPilar Sanchez-Mosquera
Pilar Sanchez-Mosquera
ACArkaitz Carracedo
Arkaitz Carracedo
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer

24 August 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
NMNatalia Martín-Martín
Natalia Martín-Martín
MPMarco Piva
Marco Piva
JUJelena Urosevic
Jelena Urosevic
PAPaula Aldaz
Paula Aldaz
JSJames Sutherland
James Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.

1 April 2005 in Nutrition
Verified
Journal Article
Closed access
MMMaría Teresa Macarulla
María Teresa Macarulla
AFAlfredo Fernandez-Quintela
Alfredo Fernandez-Quintela
AZAmaia Zabala
Amaia Zabala
VNVirginia Navarro
Virginia Navarro
EEEnrique Echevarría
Enrique Echevarría
MPMaria P. Portillo
Maria P. Portillo